Meeting Banner
Abstract #0513

Post-Bevacizumab &[Delta]T1 Maps Detect Residual Contrast Enhancement and Predict Survival in Recurrent Glioblastoma

Davis C. Woodworth1, 2, Timothy F. Cloughesy3, Robert J. Harris1, 2, Whitney B. Pope1, Albert Lai3, Phioanh (Leia) Nghiemphu3, Benjamin M. Ellingson1, 2

1Dept. of Radiological Sciences, UCLA, Los Angeles, CA, United States; 2Biomedical Physics, UCLA, Los Angeles, CA, United States; 3Neurology, UCLA, Los Angeles, CA, United States

Bevacizumab, a VEGF inhibitor, is a common second line treatment for glioblastoma after recurrence; however, bevacizumab results in reduction in contrast enhancement, which makes it difficult to assess true tumor burden and response to therapy. In the current study we explore the use of post-bevacizumab delta-T1 maps, where pre-contrast T1w images are subtracted from post-contrast T1w images, in 101 patients with recurrent glioblastoma. Results suggest delta-T1 maps reliably detect subtle contrast enhancement not apparent on normal post-contrast T1w images. Further, patients with a volume of delta-T1 hyperintense tumor greater than 15cc have a significantly shorter progression-free and overall survival.

Abstract PDF Presentation Video

Keywords

accurate accurately administration affects aggressive alone although anti appreciable appreciably approved audience biomedical blood board body brain burden calculation cerebral chemotherapy circumventing clearly clinical common confirmed context contoured contours contrast criteria cure database date days decreased defined degree delta demarcate dept detect deviation discern dividing dramatic enhancement enhancing enrolled entire every examined form free great greater gross hazard histology hypothesized identified illustrated implement improves informed inhibitor initial institutional intensity involve involving isolated issues lack larger lesions long malignant manual manually mapping maps median months need neurology next normalization normalized often oncologists option otherwise overall paired participating particularly patients percentile permeability physics pope post predict predictive products progression quantification quantify radiological rank recurrence recurrent reduction regular resection residual response review sciences separating short shorter signed significantly smaller specifically statistical stratifies subtracting subtraction suggesting surgical survival target technologies term therapies therapy throughout timothy treatment tumor tumors undetected vascular volume volumes weeks whether wise